By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Life sciences “industrials” — companies that supply key materials, services, and technology platforms for biopharma developers — traditionally start as bootstrap enterprises. Until recently, they have primarily relied on seed money from angels, family, various other small-scale investors, grant money, and early income to fund their entry and subsequent growth. But the industrials or supplier sector of this industry, in a significant change from the past, is now receiving an extra financial boost from VC funding.